Preview

Научно-практическая ревматология

Расширенный поиск

Несвоевременные мысли о применении генно-инженерных биологических препаратов при ревматических болезнях

https://doi.org/10.14412/1995-4484-2016-361-366

Полный текст:

Аннотация

В течение последних двух десятилетий разработан целый ряд инновационных генно-инженерных биологических препаратов, внедрение которых в клиническую практику позволило существенно улучшить результаты лечения ревматических болезней. В то же время отмечается нарастание числа сообщений о связанных с их применением неблагоприятных реакциях, нередко парадоксальных (показанное при многих аутоиммунных процессах назначение этих препаратов может вызвать аналогичные аутоиммунные процессы ).

Об авторах

Ю. В. Муравьев
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
115522 Москва, Каширское шоссе, 34А


Л. А. Муравьева
Центральное поликлиническое отделение МБУЗ «Химкинская центральная клиническая больница»
Россия
141400 Московская область, Химки, ул. Чкалова, 2/21


Список литературы

1. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum. 2005;34:7-11. doi: 10.1016/j.semarthrit.2005.01.003

2. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs. 2005;65:661-94. doi: 10.2165/00003495-200565050-00006

3. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;95:2275-85. doi: 10.1001/jama.295.19.2275

4. Genovese MC, Bathon JM, Fleischmann RM, et al. Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005;32:1232-42.

5. Lebwohl M, Gottlieb A, Wallis W, Zitnik R. Safety and efficacy of over 7 years of etanercept therapy ina global population of patients with rheumatoid arthritis. J Am Acad Dermatol. 2005;52:195. doi: 10.1016/j.jaad.2004.10.788

6. Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol. 2006;18:96-100. doi: 10.1097/01.bor.0000198007.73320.6e

7. Rubin RL. Drug-induced lupus. Toxicology. 2005;209:135-47. doi: 10.1016/j.tox.2004.12.025

8. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part 1. Arthritis Rheum. 2008;58:15-25. doi: 10.1002/art.23177

9. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part 2. Arthritis Rheum. 2008;58:26-35. doi: 10.1002/art.23176

10. Ioannidis JP, Karassa FB, Druyts E, et al. Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat Rev Rheumatol. 2013;11:665-73. doi: 10.1038/nrrheum.2013.134

11. Light DW. Pharmaceutical sales representatives and patient safety. J Gen Intern Med. 2013;28 (11):1394. doi: 10.1007/s11606-013-2559-1

12. Mintzes B, Lexchin J, Wilkes MS, et al. Pharmaceutical sales representatives and patient safety. J Gen Intern Med. 2013;28(11):1395. doi: 10.1007/s11606-013-2563-5

13. Mintzes B, Lexchin J, Sutherland J, et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med. 2013;28(10):1368-75. doi: 10.1007/s11606-013-2411-7

14. Khan NA, Lombeida JI, Singh M, et al. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. Arthritis Rheum. 2012;64:2059-67. doi: 10.1002/art.34393

15. Schmucker C, Schell LK, Portalupi S, et al. Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries. PLoS One. 2014;9(12):e114023. doi: 10.1371/journal.pone.0114023

16. Gotzsche PC. Reference bias in reports of drug trials. Br Med J (Clin Res Ed). 1987;295(6599):654-6. doi: 10.1136/bmj.295.6599.654

17. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308:898-908. doi: 10.1001/2012.jama.10857

18. Yadav S, Singh S, Harmsen WS, et al. Effect of medications on risk of cancer in patients with inflammatory bowel diseases: A population-based cohort study from Olmsted County, Minnesota. Mayo Clin Proc. 2015 Jun;90(6):738-46. doi: 10.1016/j.mayocp.2015.03.024. Epub 2015 May 9.

19. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2011;63:1479-85. doi: 10.1002/art.30310

20. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794. doi: 10.1002/14651858.CD008794.pub2

21. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242-51. doi: 10.1097/MD.0b013e3181441a68

22. Ramos-Casals M, Brito-Zeron P, Soto MJ, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22(5):847-61. doi: 10.1016/j.berh.2008.09.008

23. Ramos-Casals M, Perez-Alvarez R, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a doubleedged sword? Autoimmun Rev. 2010;9:188-93. doi: 10.1016/j.autrev.2009.10.003

24. Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore). 2008;87:345-64. doi: 10.1097/MD.0b013e318190f170

25. Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25(1):56-64. doi: 10.1097/BOR.0b013e32835b1366

26. Mendonc JA, Marques-Neto JF, Samara AM, Appenzeller S. Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis. Rheumatol Int. 2012;32:815-8. doi: 10.1007/s00296-011-1812-3

27. Parekh K, Ching D, Rahman MU, Stamp LK. Onset of Wegener's granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event? Rheumatology (Oxford). 2010;49:1785-7. doi: 10.1093/rheumatology/keq101

28. Fonollosa A, Artaraz J, Les I, et al. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Inflamm. 2012;20:44-8. doi: 10.3109/09273948.2011.623212

29. Bessissow T, Renard M, Hoffman I, et al. Review article: nonmalignant haematological complications of antitumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36:312-23. doi: 10.1111/j.1365-2036.2012.05189.x

30. Illei GG, Shirota Y , Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542-52. doi: 10.1002/art.27221

31. Муравьев ЮВ, Гридина ГИ, Каратеев ДЕ. Тромбоэмболия – неожиданная неблагоприятная реакция, возникшая в период применения ингибитора фактора некроза опухоли α адалимумаба. Научно-практическая ревматология. 2013;51(3):354-6 [Muravyev YV, Gridina GI, Karateev DE. Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor α inhibitor adalimumab. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):354-6 (In Russ.)]. doi: 10.14412/1995-4484-2013-1514

32. Malisiewicz B, Murer C, Pachlopnik Schmid J, et al. Eosinophilia during psoriasis treatment with TNF antagonists. Dermatology. 2011;223:311-5. doi: 10.1159/000334805

33. Aouba A, de Bandt M, Aslangul E, et al. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford). 2003;42:800-2. doi: 10.1093/rheumatology/keg187

34. Oda Y, Urushidani Y, Ooi S, et al. Hemophagocytic lymphohistiocytosis in a rheumatoid arthritis patient treated with infliximab. Intern Med. 2012;51:655-7. doi: 10.2169/internalmedicine.51.5687

35. Numakura T, Matsuura Y, Takiguchi H, et al. Tuberculosis associated with hemophagocytic syndrome complicated by treatment with infliximab. Nihon Kokyuki Gakkai Zasshi. 2010;48:449-53.

36. Araki D, Fujii H, Matsumura M, et al. Etanercept-induced lupus accompanied by hemophagocytic syndrome. Intern Med. 2011;50:1843-8. doi: 10.2169/internalmedicine.50.5430

37. Sandhu C, Chesney A, Piliotis E, et al. Macrophage activation syndrome after etanercept treatment. J Rheumatol. 2007;34:241-2.

38. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30:401-3.

39. Mehta BM, Hashkes PJ, Avery R, Deal CL. A 21-year-old man with Still's disease with fever, rash, and pancytopenia. Arthritis Care Res (Hoboken). 2010;62:575-9. doi: 10.1002/acr.20001

40. Bosch X, Saiz A, Ramos-Casals M; BIOGEAS Study Group. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011;7:165-72. doi: 10.1038/nrneurol.2011.1

41. Nozaki K, Silver RM, Stickler DE, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci. 2011;342:352-5. doi: 10.1097/MAJ.0b013e31822b7bb8

42. Brigo F, Bongiovanni LG, Cerini R, et al. Infliximab-related seizures: a first case study. Epileptic Disord. 2011;13:214-7.

43. Stubgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281-92. doi: 10.1002/mus.20924

44. Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, et al. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med. 2011;124:386-94. doi: 10.1016/j.amjmed.2010.11.028

45. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41:256-64. doi: 10.1016/j.semarthrit.2010.11.002

46. Hadjinicolaou AV, Nisar MK, Parfrey H, et al. Noninfectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford). 2012;51:653-62. doi: 10.1093/rheumatology/ker290

47. Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during antitumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41:503-10. doi: 10.1016/j.semarthrit.2011.05.005

48. Wendling D, Dernis E, Prati C, et al. Onset of inflammatory eye disease undertocilizumab treatment for rheumatologic conditions: a paradoxical effect? J Rheumatol. 2011;38:2284. doi: 10.3899/jrheum.110170

49. Van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2011;38:1441-6. doi: 10.3899/jrheum.100809

50. Toussirot E, Houvenagel E, Goö b V, et al. Development of inflammatory bowel disease during anti-TNF-a therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine. 2011 [Epub ahead of print].

51. Sekkach Y, Hammi S, Elqatni M, et al. Ulcerative colitis: exceptional consequence after rituximab therapy. Ann Pharm Fr. 2011;69:265-9. doi: 10.1016/j.pharma.2011.06.005

52. Bhalme M, Hayes S, Norton A, et al. Rituximab-associated colitis. Inflamm Bowel Dis. 2012 [Epub ahead of print].

53. ElFassi D, Nielsen CH, Junker P, et al. Systemic adverse events following rituximab therapy in patients with Graves' disease. J Endocrinol Invest. 2011;34:e163-7.

54. Goetz M, Atreya R, Ghalibafian M, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007;13:1365-8. doi: 10.1002/ibd.20215

55. Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010;126:e243-6. doi: 10.1542/peds.2009-3395

56. Fiehn C, Vay S. Induction of inflammatory bowel disease flares by golimumab: report of three patients with enteropathic spondylarthritis or ankylosing spondylitis and comorbid colitis. Arthritis Rheum. 2011;63:3640-1. doi: 10.1002/art.30546

57. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-40. doi: 10.1016/j.semarthrit.2010.04.003

58. Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantarpustulosis associated with tumor necrosis factor-a inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2011;67:e179-85. doi: 10.1016/j.jaad.2011.05.038

59. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving antitumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209-15. doi: 10.1136/ard.2007.087288

60. Thomas L, Canoui-Poitrine F, Gottenberg JE, et al. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol. 2012;39:893-8. doi: 10.3899/jrheum.111347

61. Kato K, Satoh T, Nishizawa A, Yokozeki H. Psoriasiform drug eruption due to abatacept. Acta Derm Venereol. 2011;91:362-3. doi: 10.2340/00015555-1042

62. Konsta M, Rallis E, Karameris A, et al. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation. J Eur Acad Dermatol Venereol. 2012;26:257-8. doi: 10.1111/j.1468-3083.2011.04042.x

63. Brigant F, Clavel G, Chatelain D, et al. A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept. Dermatol Online J. 2011;17:11.

64. Gonzalez-Lopez MA, Martinez-Taboada VM, Gonzalez-Vela MC, et al. Newonset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2008;158:1146-8. doi: 10.1111/j.1365-2133.2008.08470.x

65. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012;39:481-92. doi: 10.1111/j.1600-0560.2012.01894.x

66. Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venereol. 2010;90:183-5. doi: 10.2340/00015555-0777

67. Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev. 2014;13(8):873-9. doi: 10.1016/j.autrev.2014.05.005


Для цитирования:


Муравьев Ю.В., Муравьева Л.А. Несвоевременные мысли о применении генно-инженерных биологических препаратов при ревматических болезнях. Научно-практическая ревматология. 2016;54(3):361-366. https://doi.org/10.14412/1995-4484-2016-361-366

For citation:


Muravyev Yu.V., Muravyeva L.A. TARDY IDEAS ON THE USE OF BIOLOGICAL AGENTS IN RHEUMATIC DISEASES. Rheumatology Science and Practice. 2016;54(3):361-366. (In Russ.) https://doi.org/10.14412/1995-4484-2016-361-366

Просмотров: 306


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)